Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro.
We have examined the effects of either brain-derived neurotrophic factor (BDNF), the BB-isoform of platelet-derived growth factor (PDGF-BB), or a combination of these growth factors on the survival and the morphological development of embryonic striatal neurons grown under serum-free culture conditions. Striatal neurons were identified using immunocytochemistry for "dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein with a molecular weight of 32 kilodalton" (DARPP-32). BDNF and PDGF-BB promoted the survival of DARPP-32-positive neurons, with the magnitude of their effects being comparable. A combination of these growth factors exerted no significant additive effects on cell survival. BDNF stimulated morphological differentiation of DARPP-32-containing neurons by increasing the length of neurites, the number of branching points on the neurites, and the soma area. By contrast, PDGF-BB increased the neurite length and the cell body area, but not the number of branching points. BDNF also protected striatal neurons from excitotoxicity induced by N-methyl-D-aspartate, whereas PDGF-BB had no effect under the same treatment conditions as those for BDNF. Thus, BDNF is trophic for striatal DARPP-32-containing neurons in vitro by enhancing the survival, morphological differentiation and resistance to excitotoxicity, and its mechanisms of action are probably different from those of PDGF-BB.
Nakao
N
N
Department of Medical Cell Research, University of Lund, Sweden.
Brundin
P
P
Funa
K
K
Lindvall
O
O
Odin
P
P
D000818:Animals; D000077214:Becaplermin; D015415:Biomarkers / Q000737:chemistry; D019208:Brain-Derived Neurotrophic Factor; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000737:chemistry / Q000166:cytology / Q000187:drug effects*; D016895:Culture Media, Serum-Free; D051937:Dopamine and cAMP-Regulated Phosphoprotein 32; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000032:analysis* / Q000494:pharmacology*; D009474:Neurons / Q000737:chemistry / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010750:Phosphoproteins / Q000032:analysis*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology
D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D016895:Culture Media, Serum-Free; D051937:Dopamine and cAMP-Regulated Phosphoprotein 32; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D010750:Phosphoproteins; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin